Proposed Solutions to the Access Challenges Facing Cancer Medicines in Europe
Janssen’s EMEA market access head Martin Price outlines the regulatory changes that need to be made for patients across Europe to better access cutting-edge cancer medicines. Recent advances in medical science are the driving force behind the research and successful development of innovative cancer treatments in Europe. By targeting the specific characteristics of the…
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed